Floatz logo

Peluntamig

Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phanes TherapeuticsPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 1/2CC
ETOPOSIDE
Phanes Therapeutics
Phase 1/2CC
immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific;
Phanes Therapeutics
Phase 1/2CC
Atezolizumab
Phanes Therapeutics
Phase 1/2CC

Same molecule, other indications

Peluntamig is also rated in:

Neuroendocrine Carcinomas (NEC)Dormant
CCC
Indicative ·
48 / 100
View asset →
Large Cell Neuroendocrine Cancer (LCNEC)Dormant
CC
Indicative ·
47 / 100
View asset →
Neuroendocrine Prostate Cancer (NEPC)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →